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Introduction: Fine-needle aspiration cytology (FNAC) is the primary means to distinguish benign from
malignant thyroid nodules. However, adjunctive diagnostic tests are needed as 20e40% of FNAC are
inconclusive. RAS mutations have been described in differentiated thyroid cancer and they could be used
as tumor markers. However, their prevalence varies widely among studies, probably as a result of the
detection methods used. We investigated whether the pyrosequencing method can be applied to detect
NRAS and KRAS mutations in thyroid aspirates.
Patients and methods: A total of 37 thyroid aspirates, including benign hyperplastic nodules (HBN,
N ¼ 16) and follicular thyroid carcinomas (FTC, N ¼ 21) were analyzed for the presence of NRAS61 and
KRAS13 mutations.
Results: A RAS mutation was found in 31% and 62% of BN and FTC respectively. Most samples displayed a
percentage of mutated alleles lower than 50% (median ¼ 30.8% and 15.3% in FTC and HBN respectively), a
result compatible with the presence of extra-nodular cells contaminating the FNA or with the subclonal
nature of both types of thyroid nodules.
Discussion: Pyrosequencing is a reliable assay to detect RAS mutations in ﬁne-needle thyroid aspirates.
Conclusions: The low speciﬁcity and sensitivity limit the power of this test to distinguish between FTC
and benign nodules in inconclusive FNACs.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Fine-needle aspiration cytology (FNAC) is the primary diag-
nostic means in a large number of different tissues lesions,
including thyroid nodules [1e4]. A correct diagnosis is not always
achieved by microscope observation of conventionally stained
cytology smears, and alternative tools are needed [5e7]. Incon-
clusive cytology occurs in about 20% of thyroid FNAC, especially
when Hashimoto's thyroiditis is concomitant [8,9]. Diagnostic
thyroidectomy, a disabling surgical procedure sometime accom-
panied by complications is necessary in inconclusive FNAC
[10e12]. In the last decades, the diagnostic, prognostic and
therapeutic utility of a number of proteins and altered genes
expressed in thyroid cancer have been investigated [13e16].by Elsevier Ltd. All rights reservedAmong others, RAS mutations are promising as they are
expressed in papillary thyroid cancer (PTC) and more importantly
in follicular thyroid cancer (FTC) [17e20]. Besides FTC, RAS mu-
tations have been detected also in thyroid adenomas, limiting its
clinical utility as diagnostic tool. The prevalence of RAS mutations
varies widely among studies, probably as a result of the detection
methods used. This is especially true for tissue samples con-
taining a mixture of thyroid and non-thyroid cells as occurs in
the presence Hashimoto's i. A previous study demonstrated that
pyrosequencing is a reliable assay to detect a single nucleotide
polymorphism in a thyroid sample contaminated by lymphoid
cells [21]. In this study, we determined whether pyrosequencing
analysis can be applied in ﬁne-needle thyroid aspirates to
distinguish FTC from benign hyperplastic nodules (HBN). To this
purpose we searched for the presence of NRAS61 and KRAS [13]
mutations by pyrosequencing in a series of FTC and HBN ﬁne-
needle thyroid aspirates..
Table 2
Patients and deﬁnitive histology diagnosis.
HBN FTC
N 16 21
Gender (F/M) 13/3 16/5
Stage 1 5
2 9
3 3
4 0
HBN, benign hyperplastic nodules; FTC, follicular thyroid carcinoma.
Table 3
RAS mutation in cytology specimens. N, (%). Assays were performed in triplicates.
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2.1. Patients and FNAC
Patients were entered in the study after giving their consent and
with approval from the institutional review boards. Cytology
samples were obtained using a syringe with a 22-gauge needle
passed three to four times. Aspirates were used for cytological ex-
amination and the needle was then washed in TRI Reagent buffer
(Sigma) and stored at 20  C until DNA extraction. After deﬁnitive
histological diagnosis, 37 samples were retrieved and used (16
benign hyperplastic nodules HBN; 21 follicular thyroid carcinomas,
FTC). Lymphoreticular cells in the FNAC of selected samples were
sporadic and less than 1% of thyrocytes.Mutations HBN
N ¼ 16
FTC
N ¼ 21
NRAS61 1, (6.2) 5, (23.8)
KRAS13 4, (25.0) 3, (14.3)
Total RAS 5, (31.2) 8, (38.0)
HBN, benign hyperplastic nodules; FTC, follicular thyroid carcinoma.2.2. DNA extraction and detection of RAS mutations
DNA extraction was performed according to the TRI Reagent
manufacturer's recommendations. The ﬁnal pellet was resus-
pended in 10 ml diethyl-pyrocarbonate (DEPC) water. Pyrose-
quencing was performed as described in detail [22]. Brieﬂy,
50e100 ng genomic DNA was ampliﬁed by PCR with, forward
primer and reverse 5-biotinylated primer at 10 mM concentration,
and 2.5 U Taq Polymerase Recombinant (VWR, Milan, Italy)
(Table 1). PCR were performed in a TC-4000 Thermal Cycler (Bibby
Scientiﬁc, Milan, Italy), with an initial denaturation of 5 min at
94 C and subsequent denaturation for 20 s at 94 C, annealing for
20 s at 61 C, and extension for 30 s at 72 C. Twenty microliters of
biotinylated PCR product were immobilized on streptavidin-coated
Sepharose high-performance beads (Diatech), processed to obtain a
single stranded DNA using the PSQ 96 Sample Preparation Kit
(Diatech), according to the manufacturer's instructions, and incu-
bated under shaking at room temperature for 10 min in binding
buffer. Hybridization to sequencing primers and sequencing-by-
synthesis reaction of the complementary strand was automati-
cally performed on a PSQ 96MA instrument (Biotage, Uppsala,
Sweden). The cut-off was set at 10%, corresponding to the mean
percentage of normal tissues plus 2 SD. Samples were considered
positive when the RASmutated alleles were 10% with a SD < 10%.3. Results
We analyzed for the presence of NRAS mutation at position 61
and KRAS at position 13, a total of 37 thyroid aspirates from 16 HBN
and 21 FTC (Table 2). The search for RAS mutations was performed
by pyrosequencing in all 37 samples in triplicate (Table 3). A total of
13 mutations was detected. Of 16 HBN, NRAS61 mutation was
detected in 1 and KRAS [13] in 4. A RAS mutation was detected in 8
of the 21 FTC (38%), of which 5 NRAS61 and 3 KRAS [13] mutations.
Mutated NRAS61alleles were present in the range 50 to 11.3% of total
NRAS with a median of 33.6%. Mutated KRAS [13]alleles wereTable 1
PCR primers and sequencing primers.
Gene PCR primers Sequencing primers
NRAS exon 2 Forward: 50-biotin-GGTGAAACCTG
TTTGTTGGACATA-30
50-AGAAGAGTACAGTGC
CATG-30
Reverse: 50-AATACATGAGGAC
AGGCGAAGG-30
KRAS exon 1 Forward: 50-TATAAACTTGTGGTA
GTTGGA-30
50-TGTGGTAGTTGG
AGC-30
Reverse: 50-biotin-GATCATATTC
GTCCACAAAATGA-30present in the range 29 to 14.6% of total KRAS alleles with a median
of 15.3%.4. Discussion
Ras proto-oncogenes are key components in the regulation of
cell growth and differentiation of a number of different cell types
[23]. Activating mutations of the Ras proto-oncogene have been
identiﬁed in up to 35% human tumors. They are present in different
benign and malignant tumors and represent a possible hallmark of
tumor transformation, potentially useful for diagnostic and prog-
nostic purposes.
RAS mutations have been demonstrated in human thyroid tu-
mors and their oncogenic potential has been demonstrated in both
in vivo and in vitro experiments [17,19,24]. However, the prevalence
and speciﬁcity of RASmutations are quite variable in the literature,
making difﬁcult its utility as diagnostic tool. A major limitation for
the study of RAS mutations in thyroid tumors is the different
detection methods employed. The most popular are the direct
sequencing of genomic DNA by dye-terminator and by single-
strand conformation polymorphism (SSCP). However, both have
limitations. Direct sequencing is the gold standard to detect a single
nucleotide mutation. However, this method is not sensitive and it is
unable to detect the mutation in thyroid aspirates when largely
contaminated by non-tumoral cells [25,26]. Conventional
sequencing usually detects genetic mutations at a rate of >20%, a
threshold that can limit its application to thyroid biopsies.
Contamination with non-tumor cells occurs regularly in ﬁne-
needle biopsies when the needle track through the gland is long
or when a Hashimoto's thyroiditis is concomitant [21,22]. In these
circumstances, a more sensitive method such as pyrosequencing is
more appropriate. Besides sample contamination by non-tumoral
cells, the detection of genetic alterations can be impaired by the
heterogeneity of the tumor. Experimental evidences are in favor of
a genetic intratumor heterogeneity of benign thyroid nodules and
papillary thyroid carcinomas [27e32]. BRAF mutation at position
1799 (BRAFV600E) has been reported to be a subclonal event in some
recent studies, sometime concomitant with other oncogenes.
Concomitant BRAFV600E and RET/PTC rearrangement has been
detected in 19.4% of PTC, while concomitant BRAFV600E and RAS is
infrequently [28,33,34]. The subclonal nature of BRAF and RAS
mutation is not restricted to PTC. Single cell analysis demonstrated
a subclonality of both oncogenes in a relevant fraction of
A. Guerra et al. / International Journal of Surgery 12 (2014) S91eS94 S93melanomas [35e37]. Although our data demonstrate that most of
samples analyzed are composed of a mixture of cells with and
without RAS mutations, the presence of non-thyroid or non-
nodular cells in the samples prevents to state that although RAS
mutation, as BRAFV600E is a subclonal event. In the light of these
considerations and our results, its high sensitivity makes pyrose-
quencing a reliable method to detect RAS mutations if FNA. How-
ever, its clinical utility as a diagnostic tool is strongly limited by the
unrestricted occurrence of RAS mutations to FTC. Benign hyper-
plastic nodules harboring RASmutations have been proposed to be
transition lesions requiring an aggressive treatment. In the absence
of clear evidence that such nodules can turn into malignant nod-
ules, they should be considered benign and subjected to a more
stringent follow up.
In conclusion, pyrosequencing is a reliable method to detect RAS
mutations in FNA. It is not helpful to reﬁne an inconclusive
cytology, however it can identify benign nodules that need a more
stringent follow up.Ethical approval
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